Christoph Sarrazin

Summary

Affiliation: Frankfurt am Main
Country: Germany

Publications

  1. ncbi Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients
    Christoph Sarrazin
    Medizinische Klinik 1, J W Goethe University Hospital, Frankfurt am Main, Germany
    J Hepatol 54:415-21. 2011
  2. ncbi Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus
    Christoph Welsch
    Department of Computational Biology and Applied Algorithmics, Max Planck Institute for Informatics, 66123 Saarbrucken, Germany
    Genome Biol 9:R16. 2008
  3. ncbi Evaluation of an automated, highly sensitive, real-time PCR-based assay (COBAS Ampliprep/COBAS TaqMan) for quantification of HCV RNA
    Christoph Sarrazin
    Medizinische Klinik I, Klinikum der J W Goethe Universitat, Theodor Stern Kai 7, 60590 Frankfurt am Main, Germany
    J Clin Virol 43:162-8. 2008
  4. ncbi Improved responses to pegylated interferon alfa-2b and ribavirin by individualizing treatment for 24-72 weeks
    Christoph Sarrazin
    Klinikum der J W Goethe Universitat, Medizinische Klinik 1, Frankfurt am Main, Germany
    Gastroenterology 141:1656-64. 2011
  5. ncbi Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy
    Christoph Sarrazin
    Department of Internal Medicine, J W Goethe University Hospital, Frankfurt, Germany
    J Hepatol 52:832-8. 2010
  6. ncbi Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-α and the protease inhibitors boceprevir or telaprevir
    Wolf Peter Hofmann
    Department of Internal Medicine I, Goethe University Hospital, Frankfurt, Germany
    Antivir Ther 16:695-704. 2011
  7. ncbi Clinical utility of the ARCHITECT HCV Ag assay for early treatment monitoring in patients with chronic hepatitis C genotype 1 infection
    Johannes Vermehren
    Medizinische Klinik 1, Klinikum der JW Goethe Universität, Frankfurt am Main, Germany
    J Clin Virol 55:17-22. 2012
  8. ncbi Screening for IL28B gene variants identifies predictors of hepatitis C therapy success
    Alexandra Doehring
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, Goethe University, Frankfurt, Germany
    Antivir Ther 15:1099-106. 2010
  9. ncbi Serum microRNA-21 as marker for necroinflammation in hepatitis C patients with and without hepatocellular carcinoma
    Verena Bihrer
    Department of Medicine I, University of Frankfurt M, Frankfurt, Germany
    PLoS ONE 6:e26971. 2011
  10. ncbi Role of nucleoside transporters SLC28A2/3 and SLC29A1/2 genetics in ribavirin therapy: protection against anemia in patients with chronic hepatitis C
    Alexandra Doehring
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University Hospital, Frankfurt am Main, Germany
    Pharmacogenet Genomics 21:289-96. 2011

Detail Information

Publications56

  1. ncbi Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients
    Christoph Sarrazin
    Medizinische Klinik 1, J W Goethe University Hospital, Frankfurt am Main, Germany
    J Hepatol 54:415-21. 2011
    ..The importance of three IL28B single nucleotide polymorphisms (rs8099917, rs12980275 and rs12979860) for HCV genotype 2/3-infected patients is unknown...
  2. ncbi Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus
    Christoph Welsch
    Department of Computational Biology and Applied Algorithmics, Max Planck Institute for Informatics, 66123 Saarbrucken, Germany
    Genome Biol 9:R16. 2008
    ..These mutations are located in the protein interior and far away from the ligand binding pocket...
  3. ncbi Evaluation of an automated, highly sensitive, real-time PCR-based assay (COBAS Ampliprep/COBAS TaqMan) for quantification of HCV RNA
    Christoph Sarrazin
    Medizinische Klinik I, Klinikum der J W Goethe Universitat, Theodor Stern Kai 7, 60590 Frankfurt am Main, Germany
    J Clin Virol 43:162-8. 2008
    ..Diagnosis of hepatitis C virus (HCV) infection and its therapy is based on qualitative and quantitative measurement of HCV RNA...
  4. ncbi Improved responses to pegylated interferon alfa-2b and ribavirin by individualizing treatment for 24-72 weeks
    Christoph Sarrazin
    Klinikum der J W Goethe Universitat, Medizinische Klinik 1, Frankfurt am Main, Germany
    Gastroenterology 141:1656-64. 2011
    ..We investigated the effects of treating patients for individualized durations...
  5. ncbi Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy
    Christoph Sarrazin
    Department of Internal Medicine, J W Goethe University Hospital, Frankfurt, Germany
    J Hepatol 52:832-8. 2010
    ..It is unknown whether shortening of treatment duration to 16/24 weeks in patients with rapid virological response at week 4 (RVR) and viral loads between 10 and 50IU/ml is possible...
  6. ncbi Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-α and the protease inhibitors boceprevir or telaprevir
    Wolf Peter Hofmann
    Department of Internal Medicine I, Goethe University Hospital, Frankfurt, Germany
    Antivir Ther 16:695-704. 2011
    ..Ribavirin increases early and sustained virological response rates in patients chronically infected with HCV who receive pegylated interferon-α and novel HCV protease inhibitors...
  7. ncbi Clinical utility of the ARCHITECT HCV Ag assay for early treatment monitoring in patients with chronic hepatitis C genotype 1 infection
    Johannes Vermehren
    Medizinische Klinik 1, Klinikum der JW Goethe Universität, Frankfurt am Main, Germany
    J Clin Virol 55:17-22. 2012
    ..However, HCV-RNA assays are time-consuming, expensive and require highly trained personnel. Quantitative determination of HCV core-antigen (HCVAg) levels may be used to supplement treatment monitoring...
  8. ncbi Screening for IL28B gene variants identifies predictors of hepatitis C therapy success
    Alexandra Doehring
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, Goethe University, Frankfurt, Germany
    Antivir Ther 15:1099-106. 2010
    ..Because HCV affects 170 million people worldwide and is a leading cause of cirrhosis and hepatocellular carcinoma, screening for prognostic factors in routine clinical practice requires rapid and reliable assays...
  9. ncbi Serum microRNA-21 as marker for necroinflammation in hepatitis C patients with and without hepatocellular carcinoma
    Verena Bihrer
    Department of Medicine I, University of Frankfurt M, Frankfurt, Germany
    PLoS ONE 6:e26971. 2011
    ..Here we correlated serum miR-21 levels with clinical parameters in patients with different stages of chronic hepatitis C virus infection (CHC) and CHC-associated HCC...
  10. ncbi Role of nucleoside transporters SLC28A2/3 and SLC29A1/2 genetics in ribavirin therapy: protection against anemia in patients with chronic hepatitis C
    Alexandra Doehring
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University Hospital, Frankfurt am Main, Germany
    Pharmacogenet Genomics 21:289-96. 2011
    ....
  11. ncbi A common HLA-DPA1 variant is associated with hepatitis B virus infection but fails to distinguish active from inactive Caucasian carriers
    Johannes Vermehren
    Pharmazentrum frankfurt ZAFES, Institut fur Klinische Pharmakologie, Klinikum der J W Goethe Universitat, Frankfurt am Main, Germany
    PLoS ONE 7:e32605. 2012
    ..Most significant associations were observed for the A alleles of HLA-DPA1 rs3077 and HLA-DPB1 rs9277535, which conferred a decreased risk for HBV infection. We assessed the implications of these variants for HBV infection in Caucasians...
  12. ncbi HVR-1 heterogeneity during treatment with telaprevir with or without pegylated interferon alfa-2a
    Christian M Lange
    J W Goethe University Hospital, Medizinische Klinik 1, Theodor Stern Kai 7, 60590 Frankfurt am Main, Germany
    Scand J Gastroenterol 46:1362-8. 2011
    ..However, the evolution of HVR-1 heterogeneity during treatment with directly acting antivirals has not been studied...
  13. ncbi Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir
    Simone Susser
    Klinikum der Goethe Universität, Medizinische Klinik 1, Theodor Stern Kai 7, 60590 Frankfurt am Main, Germany
    J Clin Virol 52:321-7. 2011
    ..Viral breakthrough during mono- and triple-therapies with PEG-interferon and ribavirin and relapse is associated with resistance...
  14. ncbi Comparison of acoustic radiation force impulse imaging with transient elastography for the detection of complications in patients with cirrhosis
    Johannes Vermehren
    Medizinische Klinik 1, Klinikum der J W Goethe Universitat, Frankfurt am Main, Germany
    Liver Int 32:852-8. 2012
    ..Acoustic radiation force impulse (ARFI) imaging is a new non-invasive, ultrasound-based method for the evaluation of liver fibrosis and cirrhosis...
  15. ncbi CD81 expression for discrimination between sustained virologic response and relapse in patients with chronic hepatitis C
    Martin Walter Welker
    Klinikum der Johann Wolfgang Goethe Universitat, Medizinische Klinik 1, Frankfurt am Main, Germany
    Scand J Gastroenterol 46:973-80. 2011
    ..The aim of this study was to prospectively investigate CD81 expression on PBMC for early discrimination between sustained virologic response (SVR) and relapse (REL) to pegylated interferon alfa-2b and ribavirin treatment...
  16. ncbi Meta-analysis shows extended therapy improves response of patients with chronic hepatitis C virus genotype 1 infection
    Harald Farnik
    Klinikum der J W Goethe Universität Frankfurt am Main, Medizinische Klinik 1, Frankfurt am Main, Germany
    Clin Gastroenterol Hepatol 8:884-90. 2010
    ..We performed a meta-analysis to determine the overall impact of extended treatment, compared with standard treatment, on virologic response rates in these patients...
  17. ncbi Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection
    Christian M Lange
    Medizinische Klinik 1, Klinikum der J W Goethe Universität Frankfurt am Main, D 60590 Frankfurt am Main, Germany
    J Hepatol 55:322-7. 2011
    ..We therefore, aimed to explore the impact of donor and recipient genotypes of these polymorphisms on hepatitis C virus (HCV) liver graft reinfection...
  18. ncbi Serum lipids in European chronic HCV genotype 1 patients during and after treatment with pegylated interferon-α-2a and ribavirin
    Christian M Lange
    Klinikum der J W Goethe Universität Frankfurt am Main, Medizinische Klinik, Frankfurt am Main, Germany
    Eur J Gastroenterol Hepatol 22:1303-7. 2010
    ..We therefore aimed to determine the impact of chronic hepatitis C and its treatment on circulating lipids in a large European cohort of HCV genotype 1 patients...
  19. ncbi Assessment of liver fibrosis and associated risk factors in HIV-infected individuals using transient elastography and serum biomarkers
    Johannes Vermehren
    Medizinische Klinik 1, Klinikum der J, W, Goethe Universitat, Frankfurt am Main, Germany
    BMC Gastroenterol 12:27. 2012
    ..Our aim was to determine the prevalence of liver fibrosis and associated risk factors in HIV-infected individuals based on non-invasive fibrosis assessment using transient elastography (TE) and serum biomarkers (Fibrotest [FT])...
  20. ncbi Antiviral strategies in hepatitis C virus infection
    Christoph Sarrazin
    Klinikum der JW Goethe Universität, Medizinische Klinik 1, Theodor Stern Kai 7, 60590 Frankfurt am Main, Germany
    J Hepatol 56:S88-100. 2012
    ..However, new drugs may be associated with troublesome side effects and drugdrug interactions, and the ideal IFN-free DAA combination remains to be found...
  21. ncbi Clinical relevance of the 2'-5'-oligoadenylate synthetase/RNase L system for treatment response in chronic hepatitis C
    Ulrike Mihm
    Medizinische Klinik I, Klinikum der Johann Wolfgang Goethe Universitat, Theodor Stern Kai 7, 60590 Frankfurt Main, Germany
    J Hepatol 50:49-58. 2009
    ..Viral RNA is cleaved by RNase L at UU/UA dinucleotides. The clinical relevance of RNase L cleavage for response to an interferon-alpha-based therapy in chronic hepatitis C is unknown...
  22. ncbi Nucleos(t)ide analogue treatment reduces apoptotic activity in patients with chronic hepatitis B
    Harald Farnik
    Medizinische Klinik 1, Klinikum der Johann Wolfgang Goethe Universitat Frankfurt, Theodor Stern Kai 7, Haus 11, 60590 Frankfurt, Germany
    J Clin Virol 52:204-9. 2011
    ..Reduction of necroinflammatory activity is a major goal of antiviral therapy of patients with chronic hepatitis B. Serum ALT does not detect all forms of cell death...
  23. ncbi Dynamics of apoptotic activity during antiviral treatment of patients with chronic hepatitis C
    Bernd Kronenberger
    Medizinische Klinik I, Klinikum der Johann Wolfgang Goethe UniversitRt, Frankfurt Main, Germany
    Antivir Ther 12:779-87. 2007
    ..Cell death during antiviral therapy of patients with chronic hepatitis C is not well understood...
  24. ncbi HLA class I allele associations with HCV genetic variants in patients with chronic HCV genotypes 1a or 1b infection
    Christian Markus Lange
    Klinikum der J W Goethe Universität Frankfurt am Main, Medizinische Klinik 1, Theodor Stern Kai 7, 60590 Frankfurt am Main, Germany
    J Hepatol 53:1022-8. 2010
    ..In the present study, we aimed to identify associations of HLA class I alleles with HCV subtypes 1a and 1b genetic variants...
  25. ncbi Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy
    Christian Markus Lange
    Klinikum der J W Goethe Universität Frankfurt am Main, Medizinische Klinik 1, Theodor Stern Kai 7, 60590 Frankfurt am Main, Germany
    J Hepatol 54:887-93. 2011
    ..We, therefore, performed a comprehensive analysis on the impact of vitamin D serum levels and of genetic polymorphisms with functional relevance within the vitamin D cascade on chronic hepatitis C and its treatment...
  26. ncbi Soluble serum CD81 is elevated in patients with chronic hepatitis C and correlates with alanine aminotransferase serum activity
    Martin Walter Welker
    Medizinische Klinik 1, Klinikum der Johann Wolfgang Goethe Universitat, Theodor Stern Kai 7, Frankfurt am Main, Germany
    PLoS ONE 7:e30796. 2012
    ..We performed a case-control study to investigate whether soluble CD81 in the exosomal serum fraction is associated with HCV replication and inflammatory activity...
  27. ncbi Ribavirin mode of action in chronic hepatitis C: from clinical use back to molecular mechanisms
    Wolf Peter Hofmann
    Department of Internal Medicine 1, Johann Wolfgang Goethe University Hospital, Frankfurt, Germany
    Liver Int 28:1332-43. 2008
    ..Furthermore, theoretical aspects from mathematical modelling of ribavirin action in chronic hepatitis C are reviewed...
  28. ncbi Development of a second version of the Cobas AmpliPrep/Cobas TaqMan hepatitis C virus quantitative test with improved genotype inclusivity
    Johannes Vermehren
    Medizinische Klinik 1, Klinikum der J W Goethe Universitat, Theodor Stern Kai 7, 60590 Frankfurt am Main, Germany
    J Clin Microbiol 49:3309-15. 2011
    ..In conclusion, CAP/CTM v2 accurately quantifies HCV RNA across all HCV genotypes, including specimens with rare polymorphisms previously associated with underquantification...
  29. ncbi Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients
    Simone Susser
    JW Goethe University Hospital, Frankfurt, Germany
    Hepatology 50:1709-18. 2009
    ..All mutations are associated with reduced replicative fitness estimated by mathematical modeling and show cross-resistance to telaprevir...
  30. ncbi The role of resistance in HCV treatment
    Johannes Vermehren
    Medizinische Klinik 1, Klinikum der J W Goethe Universitat, Theodor Stern Kai 7, 60590 Frankfurt am Main, Germany
    Best Pract Res Clin Gastroenterol 26:487-503. 2012
    ..In addition, the most recent literature and conference data on resistance profiles of DAAs in clinical development and future strategies to avoid the emergence of viral resistance are also discussed...
  31. ncbi Ultrasound evaluation of perihepatic lymph nodes during antiviral therapy with the protease inhibitor telaprevir (VX-950) in patients with chronic hepatitis C infection
    Mireen Friedrich Rust
    Department of Internal Medicine, Saarland University Hospital, Homburg Saar, Germany
    Ultrasound Med Biol 33:1362-7. 2007
    ....
  32. ncbi Highly sensitive determination of HCV protease inhibitors boceprevir (SCH 503034) and telaprevir (VX 950) in human plasma by LC-MS/MS
    Harald Farnik
    Pharmazentrum frankfurt ZAFES, Institut fur Klinische Pharmakologie, Klinikum der Johann Wolfgang Goethe Universitat Frankfurt, Theodor Stern Kai 7, Haus 74, 60590 Frankfurt am Main, Germany
    J Chromatogr B Analyt Technol Biomed Life Sci 877:4001-6. 2009
    ..It is suitable to quantify the concentrations of the hepatitis C virus protease inhibitors boceprevir and telaprevir in human plasma...
  33. ncbi Differences between two real-time PCR-based hepatitis C virus (HCV) assays (RealTime HCV and Cobas AmpliPrep/Cobas TaqMan) and one signal amplification assay (Versant HCV RNA 3.0) for RNA detection and quantification
    Johannes Vermehren
    Zentrum der Inneren Medizin, Medizinische Klinik 1, Klinikum der JW Goethe Universität, Frankfurt am Main, Germany
    J Clin Microbiol 46:3880-91. 2008
    ..The previously reported differences in the absolute quantification of samples harboring gt1 were confirmed and may be explained by different calibrations to the WHO standard...
  34. ncbi Hepatitis C virus nonstructural 5A protein and interferon resistance: a new model for testing the reliability of mutational analyses
    Christoph Sarrazin
    Medizinische Klinik II, Johann Wolfgang Goethe Universitat, 60590 Frankfurt am Main, Germany
    J Virol 76:11079-90. 2002
    ..For improvement of mutational analysis, a refined specific functional data test procedure is proposed...
  35. ncbi Multi-center evaluation of the Abbott RealTime HCV assay for monitoring patients undergoing antiviral therapy for chronic hepatitis C
    Johannes Vermehren
    Medizinische Klinik 1, Klinikum der J W Goethe Universitat, Frankfurt am Main, Germany
    J Clin Virol 52:133-7. 2011
    ..Hepatitis C virus (HCV) RNA monitoring during antiviral therapy is essential for early prediction of treatment success and failure to peginterferon alfa/ribavirin (PEG-IFN/RBV) therapy...
  36. ncbi Current therapy for hepatitis C
    Mireen Friedrich Rust
    Department of Internal Medicine, Saarland University Hospital, Kirrbergerstr, Bldg 41, 66421 Homburg Saar, Germany
    Int J Colorectal Dis 22:341-9. 2007
    ..The duration of therapy depends on the HCV genotype with currently 48 weeks for genotype 1 and 24 weeks for genotypes 2 and 3...
  37. ncbi Resistance to direct antiviral agents in patients with hepatitis C virus infection
    Christoph Sarrazin
    J W Goethe University Hospital, Medizinische Klinik 1, Frankfurt am Main, Germany
    Gastroenterology 138:447-62. 2010
    ..We review the parameters that determine resistance, genotypic and phenotypic resistance profiles of DAA agents, and strategies to avoid the selection of resistant variants...
  38. ncbi Dimerization of the hepatitis C virus nonstructural protein 4B depends on the integrity of an aminoterminal basic leucine zipper
    Martin Walter Welker
    Klinikum der Johann Wolfgang Goethe Universitat, Medizinische Klinik 1, Theodor Stern Kai 7, Frankfurt am Main 60590, Germany
    Protein Sci 19:1327-36. 2010
    ..In conclusion, our data indicate NS4B-homodimerization and that this interaction is facilitated by the aminoterminal part containing a bZIP motif...
  39. ncbi Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function
    Christian M Lange
    Klinikum der J W Goethe Universität Frankfurt am Main, Medizinische Klinik 1, Frankfurt am Main, Germany
    Hepatology 50:2001-6. 2009
    ..In contrast, Child-Pugh Score did not correlate with the development of lactic acidosis. Our data indicate that entecavir should be applied cautiously in patients with impaired liver function...
  40. ncbi Serum miR-122 as a biomarker of necroinflammation in patients with chronic hepatitis C virus infection
    Verena Bihrer
    Department of Medicine I, University of Frankfurt M, Frankfurt, Germany
    Am J Gastroenterol 106:1663-9. 2011
    ..Here, we investigated if the serum levels of miR-122 might be useful as disease parameter in patients with chronic hepatitis C virus (HCV) infection...
  41. ncbi Portal vein thrombosis as complication of romiplostim treatment in a cirrhotic patient with hepatitis C-associated immune thrombocytopenic purpura
    Georg Dultz
    Medizinische Klinik 1, Klinikum der J W Goethe Universitat, Frankfurt am Main, Germany
    J Hepatol 55:229-32. 2011
    ..We report a case of a patient with Child class B liver cirrhosis with concurrent immune thrombocytopenic purpura that developed portal vein thrombosis under therapy with the thrombopoietin receptor agonist romiplostim...
  42. ncbi Treatment predictors of a sustained virologic response in hepatitis B and C
    Annika Kau
    Zentrum der Inneren Medizin, Medizinische Klinik 1, Klinikum der JW Goethe Universität, Frankfurt am Main, Germany
    J Hepatol 49:634-51. 2008
    ..After initiation of treatment, initial viral decline with undetectable HCV-RNA at week 4 of therapy (RVR) is the best predictor of sustained virologic response independent of HCV genotype...
  43. ncbi How to use virological tools for the optimal management of chronic hepatitis C
    Philipp de Leuw
    Medizinische Klinik I, Klinikum der Johann Wolfgang Goethe Universitat, Frankfurt am Main, Germany
    Liver Int 31:3-12. 2011
    ..Rules for early discontinuation of antiviral therapy in non-responders and determination of optimal treatment durations in virologic responders have been developed for application of individualized treatment strategies...
  44. ncbi Acoustic radiation force impulse imaging for evaluation of antiviral treatment response in chronic hepatitis C
    Nicole Forestier
    Department of Internal Medicine 1, Faculty of Medicine, J W Goethe University, Frankfurt, Germany
    J Gastrointestin Liver Dis 21:367-73. 2012
    ..The aim of the present study was to demonstrate a significant difference of ARFI-values in patients with sustained-virological-response (SVR) as compared to patients without...
  45. ncbi Liver fibrosis in viral hepatitis: noninvasive assessment with acoustic radiation force impulse imaging versus transient elastography
    Mireen Friedrich-Rust
    Department of Internal Medicine 1, J W Goethe University Hospital, Theodor Stern Kai 7, 60590 Frankfurt am Main, Germany
    Radiology 252:595-604. 2009
    ....
  46. ncbi Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis
    Mireen Friedrich-Rust
    Department of Internal Medicine 1, JW Goethe University Hospital, Frankfurt, Germany
    BMC Gastroenterol 10:103. 2010
    ..While a systematic review has shown comparable results for both individual markers, there has been no direct comparison of both markers...
  47. ncbi Assessment of liver fibrosis and steatosis in PBC with FibroScan, MRI, MR-spectroscopy, and serum markers
    Mireen Friedrich-Rust
    Department of Internal Medicine 1, J W Goethe University, Frankfurt, Germany Mireen
    J Clin Gastroenterol 44:58-65. 2010
    ....
  48. ncbi Performance of transient elastography for the staging of liver fibrosis: a meta-analysis
    Mireen Friedrich-Rust
    Department of Internal Medicine I, J W Goethe University Hospital, Frankfurt, Germany
    Gastroenterology 134:960-74. 2008
    ..A meta-analysis was performed to assess the overall performance of transient elastography for the diagnosis of liver fibrosis and to analyze factors influencing the diagnostic accuracy...
  49. ncbi Contrast-enhanced sonography of adrenal masses: differentiation of adenomas and nonadenomatous lesions
    Mireen Friedrich-Rust
    Medizinische Klinik I, Klinikum der Johann Wolfgang Goethe Universitat, Theodor Stern Kai 7, 60590 Frankfurt am Main, Germany
    AJR Am J Roentgenol 191:1852-60. 2008
    ..The aim of this proof-of-principle study was to evaluate contrast-enhanced sonography in the characterization of adrenal masses...
  50. ncbi Deep Sequencing Reveals Mutagenic Effects of Ribavirin during Monotherapy of Hepatitis C Virus Genotype 1-Infected Patients
    Julia Dietz
    Department of Internal Medicine 1, J W Goethe University Hospital, Frankfurt, Germany
    J Virol 87:6172-81. 2013
    ..152). We conclude that ribavirin exerts a mutagenic effect on the virus in patients with chronic hepatitis C by facilitating G-to-A and C-to-U nucleotide transitions...
  51. ncbi Treatment of Amanita phalloides intoxication by fractionated plasma separation and adsorption (Prometheus®)
    Dominik Bergis
    Department of Internal Medicine 1, Johann Wolfgang Goethe University Hospital, Theodor Stern Kai 7, 60590 Frankfurt am Main, Germany
    J Gastrointestin Liver Dis 21:171-6. 2012
    ....
  52. ncbi High prevalence of anti-HCV antibodies in two metropolitan emergency departments in Germany: a prospective screening analysis of 28,809 patients
    Johannes Vermehren
    Medizinische Klinik 1, Klinikum der J W Goethe Universitat, Frankfurt am Main, Germany
    PLoS ONE 7:e41206. 2012
    ..The aim of this study was to assess the HCV seroprevalence in patients visiting two tertiary care emergency departments in Berlin and Frankfurt, respectively...
  53. ncbi New hepatitis C therapies in clinical development
    Johannes Vermehren
    Medizinische Klinik 1, Klinikum der J W Goethe Universitat, Theodor Stern Kai 7, 60590 Frankfurt am Main, Germany
    Eur J Med Res 16:303-14. 2011
    ..While improved formulations of current HCV therapies are also being developed, future hopes lie on the combination of direct-acting antivirals with the eventual possibility of interferon-free treatment regimens...
  54. ncbi Noninvasive assessment of liver fibrosis in patients with Fontan circulation using transient elastography and biochemical fibrosis markers
    Mireen Friedrich-Rust
    Department of Internal Medicine, JW Goethe University Clinic, Frankfurt, Germany
    J Thorac Cardiovasc Surg 135:560-7. 2008
    ..Therefore, early detection of fibrosis is essential to identify patients at risk. Transient elastography has been evaluated for noninvasive staging of liver fibrosis in a multitude of studies...
  55. ncbi Benefit of a clipping device in use in intestinal bleeding and intestinal leakage
    Jörg G Albert
    Department of Medicine I, Johann Wolfgang Goethe University Hospital and Clinics, Frankfurt, Germany
    Gastrointest Endosc 74:389-97. 2011
    ..The over-the-scope clip (OTSC) system was first used to close the access route in natural orifice transluminal endoscopic surgery and is increasingly used for other indications...
  56. ncbi Leitliniengerechte Therapie der Hepatitis C. Die Eradikation von HCV als Ziel
    Christoph Sarrazin
    Klinikum der J W Goethe Universität Frankfurt am Main, Medizinische Klinik 1, Theodor Stern Kai 7, 60590 Frankfurt am Main
    Pharm Unserer Zeit 40:52-9. 2011
    ..Durch die aktuell in der klinischen Phase II bis III befindlichen direkt antiviralen Substanzen werden sich die Heilungsraten der Therapie in naher Zukunft wesentlich verbessern...